Replimune (REPL) Net Income towards Common Stockholders (2017 - 2026)
Replimune (REPL) posted Net Income towards Common Stockholders of -$73.2 million for Q1 2026, down 3.22% sequentially from -$70.9 million in Q4 2025, and up 1.23% YoY from -$72.3 million in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Replimune has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$73.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 1.23% year-over-year to -$73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$313.9 million (down 26.95% YoY) and the FY2026 annual result came in at -$313.9 million, down 26.95% from the prior year.
- Net Income towards Common Stockholders slipped to -$73.2 million in Q1 2026 per REPL's latest filing, from -$70.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$31.7 million in Q1 2022 and troughed at -$86.7 million in Q2 2025.
- A 5-year average of -$57.8 million and a median of -$53.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders grew 11.64% in 2024, then tumbled 61.22% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$39.7 million in 2022, then fell by 28.8% to -$51.1 million in 2023, then declined by 29.77% to -$66.3 million in 2024, then slipped by 6.92% to -$70.9 million in 2025, then declined by 3.22% to -$73.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$73.2 million, -$70.9 million, and -$83.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | -69.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -69.77 Mn |
| Mar 31, 2026 | -73.22 Mn |
| Dec 31, 2025 | -70.93 Mn |
| Sep 30, 2025 | -83.10 Mn |
| Jun 30, 2025 | -86.69 Mn |
| Mar 31, 2025 | -74.13 Mn |
| Dec 31, 2024 | -66.34 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.08 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.24 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.70 Mn |
| Dec 31, 2021 | -29.67 Mn |
| Sep 30, 2021 | -29.36 Mn |